Tools   Select Another Resource Report Type

http://www.alz.org/

A non profit organization dedicated to providing support for patients and families with Alzheimer's disease, to educating the public about the disease, to funding a wide range of Alzheimer's disease related research and to finding ways to treat and eventually to prevent Alzheimer's disease. Resources include: the Alzheimer's Association Green-Field Library, a research grants program, and the Journal of the Alzheimer's Association.

Proper citation: Alzheimers Association (RRID:SCR_007398) Copy   

•   Source: SciCrunch Registry

http://iadrp.nia.nih.gov/content/about-cadro

A classification system developed by the National Institute on Aging and the Alzheimer's Association that can be used to integrate and compare Alzheimer's disease (AD) research portfolios from public and private organizations supporting AD research in the US and abroad. The CADRO was constructed as a three-tier classification system organized around seven major categories: five in research and two resource-related: * Category A. Molecular Pathogenesis and Pathophysiology of Alzheimer's Disease * Category B. Diagnosis, Assessment and Disease Monitoring * Category C. Translational Research and Clinical Interventions * Category D. Epidemiology * Category E. Care, Support and Health Economics of Alzheimer's Diseases * Category F. Research Resources * Category G. Consortia and Public Private Partnerships * Category H. Alzheimer's Disease - Related Dementias Using information from project abstracts and research aims, the above categories were stratified into research topics and these were further divided into research themes. The three levels of classification are meant to enable a fine-grained portfolio analysis that can inform strategic planning and funding decisions. The CADRO was developed as a dynamic portfolio analysis tool that can be used to: (i) capture the changing landscape of AD research funded by different organizations, (ii) identify opportunities for coordination of support for AD research, and (iii) identify funding gaps as well as areas of overlap within and across organizations.

Proper citation: CADRO (RRID:SCR_004046) Copy   

•   Source: SciCrunch Registry

http://www.alz.org/research/alzheimers_grants/overview.asp

An organization that funds research for Alzheimer's disease, provides information on new treatment strategies, provides information on caring for afflicted people, and generally increases public knowledge of disease prevention. This program financially supports new Alzheimer's studies. These research projects are selected by the Medical and Scientific Advisory Council. The council chooses which studies to address based on their potential uses in diagnostics, genetics, treatments, prevention, early detection and general enhancement of lifestyle.

Proper citation: Alzheimer's Association International Research Grant Program (RRID:SCR_008775) Copy   

•   Source: SciCrunch Registry

http://www.alz.org/research/alzheimers_grants/biomarkers-across.asp

Consortium that launched a Request for Applications (RFA) to stimulate analyses across the Alzheimer's disease (AD) and Parkinson's disease (PD) research enterprises to engage in further data analysis of existing cohorts, including, but not limited to, biomarker discovery, standardization of assays, genetic profiles, and imaging modalities. The RFA aims to build on existing momentum to leverage similar activities and increase impact across the neurodegenerative disease spectrum. It also builds on recent evidence suggesting substantial overlap between AD, PD, and other neurodegenerative diseases pathologically, but also potentially biologically. The RFA is designed to enable preliminary pilot research or proof-of-principle studies utilizing data and/or samples from two large biomarker studies, the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Parkinson's Progression Markers Initiative (PPMI), in order to garner further research support from other funding agencies. Application Deadline: March 19, 2014. Efforts under BAND include studies that: * analyze datasets to test hypotheses related to aging and neurodegenerative disorders; * seek to identify panels or pathways that may play a role in disease mechanisms, such as around inflammation; * pursue shared or disparate biochemical markers of disease risk, onset or progression; * assess potential commonalities across the disease spectrum, including around other neurological disorders such as Lewy body dementia. Recent data reported at the 2013 Alzheimer's Association's International Conference stimulated discussion in the research community about the possible cross talk between AD and PD. For example, underlying pathologies / biomarkers, such as cerebrospinal fluid (CSF) alpha-synuclein, have been measured in the sample sets collected for both diseases to help understand similarities and differences in these diseases. Furthermore, similar imaging modalities, such as MRI and PET, are being employed to interrogate changes that occur with disease progression. As therapeutic approaches are developed that may be disease-modifying for several neurodegenerative diseases, stratification of clinical trial populations based on biomarker profiles may increase the probability of success in demonstrating a beneficial effect.

Proper citation: Biomarkers Across Neurodegenerative Diseases (RRID:SCR_004015) Copy   

•   Source: SciCrunch Registry

http://iadrp.nia.nih.gov/

Database that brings together funded Alzheimer's disease (AD) research supported by public and private organizations both in the US and abroad all categorized using the Common Alzheimer's Disease Research Ontology or CADRO. Launched as a joint collaboration between the National Institute on Aging (NIH) and the Alzheimer's Association, IADRP enables users the ability to assess the portfolios of major organizations (currently 30) for areas of overlap as well as areas of opportunities in which to collaborate and coordinate in a collective effort to advance AD research.

Proper citation: IADRP (RRID:SCR_004043) Copy   

•   Source: SciCrunch Registry

http://www.alz.org/research/funding/alzheimers_research_roundtable.asp

A consortium aiming to facilitate the development and implementation of new treatments for Alzheimer's disease by collectively addressing obstacles to research and development, clinical care and public health education. The Roundtable convenes twice each year for a two-day presentation and discussion of specific topics within Alzheimer's research. Topics are selected from a list proposed and voted on by members. Roundtable members explore a broad range of Alzheimer's science topics, including: * New data and technologies that may improve the diagnosis of Alzheimer's disease, especially in its earliest and mildest stages. * Neuropsychological testing, genetic factors, and biochemical and neuroimaging biomarkers that could contribute to an earlier and more accurate Alzheimer's diagnosis. * Lessons learned about clinical trial design that may help shape future clinical trials of drugs aimed at slowing or stopping the progression of Alzheimer's. * The pros and cons of various scales as outcomes measures of clinical trials. The outputs of Roundtable meetings are published as articles in the Alzheimer's Association's journal, Alzheimer's & Dementia. The Research Roundtable also sponsors Alzheimer's Association grants. The chosen project is named Research Roundtable Sponsored Grant and the principal investigator of the project is invited to give a progress report at a Roundtable meeting.

Proper citation: Alzheimers Association Research Roundtable (RRID:SCR_004007) Copy   

•   Source: SciCrunch Registry

http://www.wikigenes.org/e/art/e/258.html

Consortium to discover and map the genes that contribute to Alzheimer's disease and completely understand the role inheritance plays. To achieve this goal, they will work to identify all the genes that contribute to the risk of developing this disease. Investigators will have access to combined genetic data from a large number of Alzheimer's disease subjects and compare it to genetic data from an equally large number of elderly people who do not have Alzheimer's. In the initial phase of the work, more than 20,000 people with Alzheimer's and about 20,000 healthy elderly subjects will be compared. As the study progresses, 10,000 additional people with Alzheimer's and the same number of healthy elderly subjects will be added to the study. The subjects for these studies come from different Alzheimer research project locations across Europe, the UK, the US, and Canada. Data is available from their 2014 publication in Translational Psychiatry at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944635/ (http://www.ncbi.nlm.nih.gov/pubmed/24495969) Currently, there is no public access to the raw individual level genetic data because of privacy considerations. Researchers working with US cohorts deposit data in the database of genotypes and phenotypes (dbGaP), where it is available to all researchers who can show that they are able to guarantee the security of the data. After scanning the DNA of over 74,000 patients and controls from 15 countries, the IGAP consortium reported 11 new regions of the genome involved in late-onset Alzheimer's disease. IGAP published its results in Nature Genetics on October 27, http://www.ncbi.nlm.nih.gov/pubmed/24162737

Proper citation: International Genomics of Alzheimers Project (RRID:SCR_004029) Copy   

•   Source: SciCrunch Registry

http://adni-info.org/

Database of the results of the ADNI study. ADNI is an initiative to develop biomarker-based methods to detect and track the progression of Alzheimer's disease (AD) that provides access to qualified scientists to their database of imaging, clinical, genomic, and biomarker data.

Proper citation: ADNI - Alzheimer's Disease Neuroimaging Initiative (RRID:SCR_003007) Copy   

•   Source: SciCrunch Registry

http://crahw.anu.edu.au/files/English_long.pdf

Assessment questionnaire used as a screening test for dementia that is filled out by a relative or other supporter who knows the patient for a minimum of 10 years to determine whether that person has declined in cognitive functioning. It lists 26 everyday situations where a person has to use their memory or intelligence. The questions on the test compare the patient''s state of mind to 10 years ago using the scale of: Much Improved A Bit Improved Not Much Change A Bit Change A Bit Worse and Much Worse. If the person is found to have significant cognitive decline, then this needs to be followed up with a medical examination to determine whether dementia is present. Scoring: * 0-3 No Cognitive Impairment * >3 Cognitive Impairment

Proper citation: Informant Questionnaire on Cognitive Decline in the Elderly (RRID:SCR_003680) Copy   

•   Source: SciCrunch Registry

http://www.alz.org/documents_custom/gpcog(english).pdf

Assessment test to screen a patient for cognitive impairment that takes less than four minutes for the cognitive test and less than two minutes for the informant interview. The cognitive test includes nine items: (1) time orientation, clock drawing: (2) numbering and spacing as well as (3) placing hands correctly, (4) awareness of a current news event and recall of a name and an address ( (5) first name, (6) last name, (7) number, (8) street, and (9) suburb). Each correct answer is valid one point leading to a maximum score of 9 (fewer points indicate more impairment). (Wikipedia) The informant interview asks six historical questions from an informant/next of kin who knows the patient well. He or she is asked to compare the patient's current function with his/her performance a few years ago. Areas that are covered in the informant interview include memory, word finding difficulties, trouble managing finances, difficulties managing medication independently and needing assistance with transportation. Scoring: * 9 No Significant Cognitive Impairment * 8-5 More Testing Required * 4-0 Cognitive Impairment

Proper citation: General Practitioner Assessment of Cognition (RRID:SCR_003679) Copy   

•   Source: SciCrunch Registry